307 Westlake Ave North
47 articles with Kineta Immuno-Oncology
Kineta Enters Research Collaboration and License Agreement with Pfizer to Develop New Cancer Immunotherapies
Kineta Immuno-Oncology, LLC (KIO), a subsidiary of Kineta, Inc., today announced that it has entered into a strategic research collaboration with Pfizer Inc. (NYSE:PFE) to develop RIG-I agonist immunotherapies for the treatment of cancer.
Phase 1 study to assess the safety, tolerability and pharmacokinetic profile of LHF-535 in healthy volunteers
Kineta Chronic Pain signed an exclusive option and license deal with Genentech. The two companies will develop Kineta’s alpha9/alpha10 nicotinic acetylcholine receptor (nAChR) antagonists to treat chronic pain.
Collaboration to develop a first-in-class α9/α10 nicotinic acetylcholine receptor antagonist for the treatment of chronic pain
Small molecule RIG-I agonist induces innate immune responses, immunogenic tumor cell death and in vivo protective immune responses in a colon carcinoma model
Kineta Immuno-Oncology Announces Presentation on Novel RIG-I Agonists at Immuno-Oncology Frontiers World Conference
The conference takes place on January 22-25 at the Hyatt Regency Hotel in Miami, FL.
Kineta RLR Agonist Demonstrates Tumor Regression And An Adaptive Immune Response In Colon Carcinoma Model
Kineta Receives Wellcome Trust Award To Advance Novel Therapeutic For Lassa Fever Into Clinical Trials
Kineta Presents Promising New Data On Novel Lassa Fever Antiviral And Broad Spectrum Innate Immune Antivirals
Kineta Announces Promising New Data For KIN 1148 – A Novel Vaccine Adjuvant For Highly Pathogenic Flu
Kineta, Seattle Children's Research Institute Present New Data Demonstrating Positive, Predictive Responses To Dalazatide In Lupus
Kineta Presents New Data Demonstrating Positive, Predictive Responses To Dalazatide In Psoriasis Patients And In Lupus, ANCA Vasculitis Studies At American College of Rheumatology Annual Meeting
Kineta To Present Updated Dalazatide Clinical Results, And Dalazatide Lupus Research At American College of Rheumatology Annual Meeting